Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,754 across all filing types
Latest filing 2026-02-13 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Results
Regulatory Filings
2026-02-13 English
Dividend
Regulatory Filings
2026-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them about the schedule of upcoming investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is about informing the exchanges and public about planned investor meetings, not the content or transcript of the meetings themselves. The document length is short (1602 characters), and it is an announcement of scheduled events rather than a detailed investor presentation or report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2026-02-11 English
Analyst call details attached
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying them of the schedule of upcoming investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is about informing the exchanges and public about planned investor meetings, not the content or transcript of the meetings themselves. The document length is short (1602 characters), and it is an announcement of scheduled events rather than a report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-02-11 English
Intimation of acquisition of equity shares of J.B. Chemicals & Pharmaceuticals Limited
Major Shareholding Notification Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the acquisition of equity shares of another company, J.B. Chemicals & Pharmaceuticals Limited. It references specific regulations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the percentage of shares acquired and aggregate holdings. The content is about notifying a change in shareholding levels due to acquisition of shares, which fits the definition of a Major Shareholding Notification. The document length is short and it is not a report or announcement of a report publication, nor does it contain financial statements or management discussion. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2026-02-03 English
General Updates
Major Shareholding Notification Classification · 100% confidence The document is an official letter addressed to stock exchanges (BSE and NSE) regarding the acquisition of equity shares of another company, J.B. Chemicals & Pharmaceuticals Limited. It references specific SEBI regulations (Listing Obligations and Disclosure Requirements) and details the percentage of shares acquired, including cumulative holdings. The content is about notifying the market and regulators of changes in share ownership levels, specifically acquisitions crossing thresholds. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full financial report or other types of filings.
2026-02-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.